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Though bile acids have been well known as digestive juice, recent studies have demonstrated that bile
acids bind to their endogenous receptors, including Farnesoid X receptor (FXR) and G protein-coupled
bile acid receptor 1 (GPBAR1; TGR5) and serve as hormone to control various biological processes,
including cholesterol/bile acid metabolism, glucose/lipid metabolism, immune responses, and energy
metabolism. Deficiency of those bile acid receptors has been reported to induce diverse metabolic
syndromes such as obesity, hyperlipidemia, hyperglycemia, and insulin resistance. As consistent,
numerous studies have reported alteration of bile acid signaling pathways in type II diabetes patients.
Interestingly, bile acids have shown to activate TGR5 in intestinal L cells and enhance secretion of
glucagon-like peptide 1 (GLP-1) to potentiate insulin secretion in response to glucose. Moreover, FXR has
been shown to crosstalk with TGR5 to control GLP-1 secretion. Altogether, bile acid receptors, FXR and
TGR5 are potent therapeutic targets for the treatment of metabolic diseases, including type II diabetes. 
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The origin of bile acids is cholesterol in the liver. By
numerous cytochrome P450 enzymes, including CYP7A1,
CYP8B1 and CYP27A1, bile acids are converted from
cholesterol in the liver [1-4]. Since bile acids are
hydrophobic and hydrophilic, they detergent to serve as
digestive juice to emulsify lipid for lipid absorption in
the intestinal tract [1]. In 1999, bile acids have been
identified as endogenous ligands for nuclear receptor,
Farnesoid X receptor (FXR) [5]. In 2006, bile acids have
been reported as endogenous ligands for G-protein bile
acid receptor (TGR5) [6]. Numerous studies have
demonstrated that bile acids promote secretion of
glucagon-like peptide 1 (GLP-1) to potentiate insulin
secretion in pancreatic β cells, leading to decreased
blood glucose level in enteroendocrinal cell lines and
animal models [7,8]. Furthermore, bile acid nuclear
receptor FXR has been recently reported to crosstalk
with TGR5 to secrete GLP-1 [9,10]. The discovery of
bile acid-mediated endocrine functions of FXR and
TGR5 has proposed new perspectives to understand
physiological roles of bile receptors to control GLP-1
secretion for the maintenance of glycemic homeostasis.
The biology of bile acids
Abovementioned, bile acids are converted from the
cholesterol in the liver by numerous cytochrome P450s.
Once bile acids are synthesized, they are immediately
conjugated to taurine or glycine for secretion into bile
canaliculi [1,3]. Bile acids are stored in the gall bladder
until feeding signal stimulates bile acid secretion for
emulsifying lipid and fat absorption in the small
intestine. When bile acids reach the small intestine, 95%
of secreted bile acids are reabsorbed and transported
back to the liver by portal vein. The remaining 5% of
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secreted bile acids is excreted with feces. Thus, total bile
acids pool size loses 5% of bile acids in each entero-
hepatic circulation. The conversion of cholesterol to bile
acids compensates equivalent amount of loss of bile
acids excreted with feces. Thus, conversion of bile acid
from cholesterol is to maintain constant bile acid pool
size [1,3].
Farnesoid X receptor: a member of nuclear receptor
superfamily
Nuclear receptors are well-known transcriptional
regulators and regulate diverse biological functions, such
as physiological homeostasis, reproduction, development,
inflammation and metabolism [11-14]. In general, nuclear
receptors function as ligand-activated transcriptional
regulator. Upon binding with their endogenous ligands,
nuclear receptors recruit various coactivators to induce
their target gene expressions. In the absence of their
ligands, nuclear receptors interact with corepressor
complex to suppress expression of their target genes.
Nuclear receptors share common structure. Though the
N-terminal domains are highly variable (A/B domain),
nuclear receptors share constitutively active transactivation
function domain (AF-1). In C-terminal domain, nuclear
receptors share ligand-dependent activation function
domain (AF2) (Figure 1). The most conserved domain
of nuclear receptors is DNA-binding domain (DBD),
which has two cysteine-Zn2+ finger motifs to recognize
specific DNA elements and allow nuclear receptors
binding to the DNA for gene regulation. Besides, DBD
domain allows nuclear receptors dimerization to control
target gene expression (Figure 1). Ligand-binding domain
is the most critical region to control transcriptional
activities of nuclear receptors. Upon binding of their
ligands, conformational changes of LBD lead to
modulation of transcriptional activities of their nuclear
receptors (Figure 1). Binding of agonist, the structure
changes of LBD recruit coactivators whereas antagonists-
bound LBD domain recruits corepressors for their gene
expression regulation. Between DBD and LBD, hinge
region is located to allow 3D structural changes of
nuclear receptors to modulate target gene expressions in
response to diverse signals (Figure 1).
FXR has been identified as a member of nuclear
receptor superfamily in 1995 [15]. In the absence of
ligands, FXR generally heterodimerizes with retinoid X
receptor (RXR) and binds to the FXR response element
(FXRE) in the promoter regions with corepressors,
including Silencing Mediators of Retinoic acid and
Thyroid hormone receptor (SMRT) and histone deacetylases
(HDACs) to suppress target gene expression [2,15-17]
(Figure 2). Upon binding with bile acids, FXR interacts
with various coactivators including histone acetyltransferase
p300, and induces target gene expressions in response to
bile acids [18] (Figure 2). FXR is ubiquitously expressed
in diverse tissues, such as liver, intestine, kidney, adipose
tissues and even immune cells, FXR-mediated bile acid
signaling plays pivotal roles to control physiological
homeostasis [17,19-24]. Previous studies have reported
that FXR-null mice exhibited dysregulated lipid homeostasis
[19]. Given that FXR controls a set of genes involved in
lipoprotein metabolism including SREBP-1c, PLTP,
SCD-1, VLDLR, ApoCII and ApoE, FXR-null mice
exhibited elevated cholesterol and triglyceride in the
blood [16,17,19,25]. Moreover, it has been shown that
FXR-null mice exhibited impaired insulin signaling and
dysregulated glucose homeostasis [19,21,22,24]. Therefore,
FXR is a key transcriptional factor to maintain lipid and
glucose homeostasis.
Cell membrane bile acid receptor TGR5
Besides nuclear bile acid receptor FXR, intrinsic bile
acid receptor is located in the cell membrane. G protein-
coupled bile acid receptor 1 (GPBAR1; TGR5) is a
member of the rhodopsin-like superfamily member of
GPCR protein and is ubiquitously expressed in diverse
tissues, including endocrine organs, muscle, adipose tissue,
immune cells, and intestinal tract [8,26-30]. Upon binding
with lithocholic acids (LCA) and taurolithocholic acid
(TLCA), TGR5 is activated to transduce signal transduction
Figure 1. Structure of Nuclear receptor superfamily.
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into the nucleus and control diverse gene expression
[30]. It has been shown that bile acids bind to TGR5 and
stimulate cAMP signaling to activate mitogen-activated
protein kinase (MAPK) pathway. Elevated intracellular
cAMP levels then activate protein kinase A (PKA) to
phosphorylate cAMP response element binding protein
(CREB) and control their target gene expressions [31].
Previously, TGR5 has been demonstrated to activate
thermogenesis and thyroid signaling pathways to enhance
energy expenditure in brown adipose tissue [6] (Figure
3). In brown adipose tissue, TGR5 activation induce
Dio2 gene expression which converts thyroxine (T4) to
tri-iodothyronine (T3), resulting in an increased energy
expenditure [6]. In addition to Dio2, numerous genes
involved in thermogenesis were largely increased by
TGR5 activation: peroxisome proliferator-activated
receptor γ coactivator-1α (PCG1α) and 1β (PGC1β),
uncoupling protein-1 (UCP1) and -3 (UCP3) and straight-
chain acyl-CoA oxidase 1 [6]. Quite interestingly, these
gene expressions were not changed in Dio2 knockout
mice, suggesting that TGR5-mediated Dio2 functions
are critical to induce numerous thermogenic gene
expressions [6]. Thus, these findings propose that bile
acids control TGR5-cAMP-Dio2-thyroid hormone signaling
axis to control energy homeostasis. Consistently, TGR5-
deficient mice exhibited severe metabolic syndromes
Figure 2. Transcriptional regulation by FXR in response to bile acids. 
Figure 3. Bile acids activate TGR5 to control thermogenesis and energy expenditure in brown adipose tissue.
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including obesity, severe insulin resistance and impaired
glucose and lipid homeostasis [32]. Therefore, these
reports clearly have proposed that TGR5 is a potent
therapeutic target for the treatment of metabolic
syndromes including obesity and type II diabetes.
Bile acids-activated TGR5 to control GLP-1 secretion
from the intestinal L cells
Besides energy expenditure, bile acids have been
reported to control incretin secretion, such as glucagon-
like peptide 1 (GLP-1). Bile acid-mediated TGR5 activation
has been demonstrated to stimulate the secretion of
GLP-1, a member of the incretin family [7,8]. Food
intake signals stimulate bile acid secretion from the gall
bladder to small intestine, which activates TGR5 in the
intestinal entero-endocrine cells to secrete insulinotropic
hormones into the bloodstream. In rodent model, bile
acids have been shown to activate TGR5 which triggers
cAMP signaling pathway to stimulate GLP-1 secretion
in intestinal L cells [7]. As consistent, synthetic TGR5
agonist, INT-777 has been shown to potentiate GLP-1
secretion in the intestinal L cells, resulting in GLP-1
receptor activation followed by an increase of insulin
secretion in pancreatic β cells [7]. These studies clearly
propose that bile acid-mediated TGR5 activation is
critical to maintain glucose homeostasis in response to
food intake via control of incretin secretion (Figure 4).
Crosstalk between FXR and TGR5 to potentiate GLP-1
secretion from the intestinal L cells
Though bile acid-mediated TGR5 activation on GLP-
1 secretion is clear, physiological roles of bile acid-
mediated FXR activation to control GLP-1 secretion is
still controversial. Previous studies have shown that
FXR activation repressed transcription of GLP-1 in
intestinal L cells [31,33]. As gene expression of GLP-1
has been reduced, FXR agonist GW4064 treatment
largely reduced GLP-1 secretion in intestinal L cells
[33]. In contrast, gut-specific FXR-null mice exhibited
elevated GLP-1 secretion, implying that FXR activation
is opposite to the TGR5 activation on the control of
GLP-1 secretion [33].
Quite interestingly, another recent study has demonstrated
that FXR activation mediated by a gut-specific FXR
agonist, Fexaramine stimulates TGR5 expression in the
intestinal L cells to potentiate TGR5-mediated cAMP
signaling and increases GLP-1 secretion in intestinal L
cells [9,10,34]. Consistently, Fexaramine treatment enhanced
GLP-1 secretion in genetic obese mice [10]. Moreover,
this study has demonstrated that Fexaramine treatment
induces gut microbiome remodeling to change bile acid
composition and increases the levels of LCA and TLCA
Figure 4. Bile acids activate TGR5 to enhance GLP-1 secretion in entoroendocrinal L cells.
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which are potent agonists for TGR5. Thus, Fexaramine-
mediated microbiome changes lead to change of bile
acids composition, resulting in enhanced TGR5 signaling
in vivo [10]. Thus, crosstalk between bile acid receptors
FXR and TGR5 potentiates GLP-1 secretion in entero-
endocrinal L cells to control glucose homeostasis
(Figure 5).
Conclusion
It has been largely accepted that bile acid signaling is
critical for the beneficial improvements of sleeve gastrectomy
surgery in rodent models [35]. Thus, physiological roles
of bile acid receptors FXR and TGR5 have been
considered as novel therapeutic targets for diverse
metabolic syndromes. Consistent with rodent models,
there are sufficient evidence suggesting that bile acid
signaling has been improved in both human patients and
animal models with bariatric surgery [36,37]. Patients
with beneficial improvements including body weight
loss and reduced blood glucose levels exhibited high
levels of circulating bile acids and enhanced GLP-1
secretion [36-38]. As consistent, patients with severe
obesity generally exhibit a decreased postprandial bile
acids levels and GLP-1 secretion [38]. Given that
crosstalk between FXR and TGR5 is critical to control
GLP-1 secretion in response to bile acid signaling
pathway, both FXR and TGR5 will provide novel
approach to develop therapeutic strategies for treatment
of metabolic syndromes such as obesity and type II
diabetes.
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